The incidence of carboplatin hypersensitivity ranges from 8 to 11% (Libra et al., 2003; Confino-Cohen et al., 2005; Schwartz et al., 2007; Koshiba et al., 2009). It would be worthwhile to design a perspective trial that could randomize patients with carboplatin hypersensitivity to receive an alternative regimen without carboplatin. Parmar et al. Blood. Int. eCollection 2022 Apr. EHA Endorsement of ESMO Clinical Practice Guidelines for Dia - LWW The overall safety of desensitization for common chemotherapy drugs and monoclonal antibodies. (2005). reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions [1]. Hypersensitivity to antineoplastic agents. doi: 10.1016/j.ygyno.2006.04.002, Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., et al. (2006). Management of uncommon chemotherapy-induced emergencies. Ann Oncol. Allergy Asthma Proc (2011) 32(1):79.10.2500/aap.2011.32.3409 Oncol. Furthermore, Moon et al. J. Clin. The characteristics of the 735 patients are presented in Table 2. These risk factors can help identify patients at greater risk of developing hypersensitivity. 105, 14721479. The cumulative incidence of severe carboplatin-related hypersensitivity was 1% after 15 cycles and 2% after 24 cycles, with a plateau beyond this cycle number, and 1% at >7,500 mg and 2% at >12,500 mg, with a plateau beyond this dose (Figures 1A,B ). Gynecol. Here's a summary of the new ESMO guidelines in 5 key areas: . Zweizig, S., Roman, L. D., and Muderspach, L. I. With a lower carboplatin infusion rate and pre-treatment with anti-allergy drugs, all of these patients were able to tolerate re-treatment with carboplatin, although 48 (78.7%) of these 61 patients developed hypersensitivity again despite the desensitization protocol. Immunotherapy 6, 905912. Published in 2020 - Ann Oncol (2020) Authors: M.E. Cancer. Bookshelf doi: 10.1006/gyno.1994.1098, Keywords: ovarian cancer, chemotherapy, carboplatin, hypersensitivity, risk factor, Citation: Tai Y-H, Tai Y-J, Hsu H-C, Lee S-P, Chen Y-Y, Chiang Y-C, Chen Y-L, Chen C-A and Cheng W-F (2017) Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. Cancer 15, 1318. Thus, the risk of severe carboplatin-related hypersensitivity may influence its usage in gynecological cancers, and it is important to develop protocols to reduce this risk, especially the risk of severe reactions. (2001). Table 6. Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. The incidence of carboplatin-related hypersensitivity correlated with cycle number and dose, with the first episode occurring at a median of 12 cycles and 6,816 mg. doi: 10.1111/j.1525-1438.2007.01063.x, Genc, D. B., Canpolat, C., and Berrak, S. G. (2012). Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordanon behalf of the ESMO Guidelines Committee. Adnan A, Acharya S, Alenazy LA, de Las Vecillas L, Giavina Bianchi P, Picard M, Calbache-Gil L, Romero-Pinedo S, Abad A-Molina AC, Kerr W, Pedicone C, Nagai J, Hollers E, Dwyer D, Castells M. J Immunol.
Chicago Cultural Center Private Events,
Santa Cruz Car Accident Yesterday,
Gooloo Jump Starter Will Not Charge,
Substantive Post Gcu,
Orthodox Greetings And Responses,
Articles E
esmo 2017 hypersensitivity